- Trial phase
- Approved (accelerated approval)
- Time to market
- Already FDA-approved (April 23, 2026); commercially available in the U.S.
- Why 3/10
- Otarmeni received FDA accelerated approval on April 23, 2026, the defining binary catalyst has passed. There is no dated PDUFA/pivotal-readout catalyst scheduled in the next ~12 months for this drug (EMA MAA is under accelerated assessment review, but no hard decision date is published). Otarmeni is an ultra-rare, zero-revenue (provided free in U.S.) gene therapy from a large-cap biotech ($64B+ market cap) with many blockbuster products; this drug is a tiny fraction of REGN's value, capping the impact score at 3.
Otarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.
Price Chart
Executive Summary
Otarmeni (lunsotogene parvec, formerly DB-OTO) is Regeneron's first-ever approved gene therapy, a one-time intracochlear infusion for OTOF-related genetic hearing loss, an ultra-rare condition affecting children and adults. The FDA granted accelerated approval on April 23, 2026, based on the CHORD Phase 1/2 trial where 80% of treated children achieved clinically meaningful hearing restoration. In a first-of-its-kind arrangement under a White House drug-pricing deal, Regeneron provides Otarmeni for free to eligible U.S. patients. The EMA is reviewing the drug under accelerated assessment for European approval. For Regeneron, a ~$64B large-cap biotech with blockbusters like Eylea HD, Dupixent, and Libtayo, Otarmeni is commercially trivial (zero-revenue model, tiny patient population) and strategically important mainly as a proof-of-concept for its broader gene therapy and hearing-loss pipeline.
How It Works
Otarmeni is a one-time gene therapy delivered as a liquid infusion directly into the inner ear. It uses a harmless, engineered virus (AAV vector) to deliver a working copy of the OTOF gene into the hearing cells of the cochlea. In patients with OTOF-related hearing loss, a faulty gene prevents production of a protein called otoferlin, which is needed for the inner ear's sensory cells to communicate with the auditory nerve. By restoring the functional gene, the therapy enables the ear to transmit sound signals to the brain.
Trial Status
Pivotal data from the ongoing Phase 1/2 CHORD trial showed 80% of 20 evaluable participants achieved hearing improvement to ≤70 dB HL pure tone audiometry thresholds at 24 weeks, meeting the primary endpoint. Responses persisted through 48 weeks in responders. The confirmatory phase of the CHORD trial is still ongoing as a post-marketing requirement for continued accelerated approval.
The Two-Sided Case
Upcoming Catalysts
- EMA CHMP opinion on Marketing Authorization Application (under accelerated assessment review, filed May 2026)
- Updated data from ongoing confirmatory CHORD trial (post-marketing requirement)
- Potential price/reimbursement decisions in ex-US markets where Regeneron may charge commercial rates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report